Pharmacogenomics of Stimulant Treatment Response
Recruiting · NCT06221358 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Calgary
View the official record on ClinicalTrials.gov →What this trial is about
The "Pharmacogenomics of Stimulant Treatment Response" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-24 with Attention deficit/hyperactivity disorder (ADHD).
Who can take part
Age range
6 Years to 24 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients will be eligible for participation if all the following are true.
- Aged 6 - 24 years.
- Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba).
- Primary diagnosis of ADHD (all types).
- Starting Methylphenidate (excluding immediate release forms) treatment.
Exclusion criteria
- Patients will be excluded from participation if any of the following are true.
- Co-occurring psychotic, bipolar or eating disorders.
- Significant risk of suicide.
- An intellectual disability, or diagnosis of autism spectrum disorder (ASD) or tics/Tourette disorders.
- Past 12-month high-risk alcohol or substance use defined as monthly or more frequent use.
- Psychotherapy or brain stimulation-based therapy initiated within 8 weeks of referral or plans to initiate/change these types of therapies during the study
- History of liver or bone marrow (hematopoietic cell) transplant as these events can result in ambiguous genomic results.
Where it is running
1 location listed.
- University of Calgary - Calgary, Alberta, Canada